BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 29, 2000
View Archived Issues
Aquila receives SBIR grant to use CD1 technology in pursuit of Chlamydia vaccine
Read More
Atrix and Elan form partnership focused on oncology and pain management
Read More
Interim results indicate that Remune + antiviral drugs may stimulate killer T-cell activity
Read More
Panacea enters agreements with Loyola covering Lewy body disorders
Read More
BioSante signs option license agreement with ID Biomedical for vaccine delivery
Read More
First selective, irreversible N-SMase inhibitor designed by German university researchers
Read More
NitroMed and UT report phase II results of NMI-870 as treatment for female sexual dysfunction
Read More
Access to commence phase III clinical trials with OraDisc
Read More
Development of CI-1033, an irreversible inhibitor of EGF tyrosine kinase activity
Read More
CEP-1347 characterized at medicinal chemistry meeting as potential antiparkinsonian
Read More
PTK-787/ZK-222584 expected to show improved selectivity as kinase inhibitor, according to SAR
Read More
ENDO 2000: focus on cardiovascular effects of examorelin
Read More
EB-1089 as a potential agent for the management of refractory thyroid carcinoma
Read More
Sch-66336 warrants further evaluation for the treatment of glioblastoma multiforme
Read More
Eniporide now claimed to be useful in NIDDM
Read More
Lilly claims new uses for LY-203638
Read More
Selective PDE4 inhibitors with bronchodilating, antiinflammatory properties
Read More
Sanofi-Synthelabo synthesizes new compounds for GABAergic transmission-associated disorders
Read More
Dual D2 and 5-HT1A receptor partial agonists claimed for depression and anxiety
Read More
Oxazolidinone antibacterial agents from Bayer
Read More
More neuraminidase inhibitors in development at Gilead
Read More
Korean laboratory presents new and improved proton pump inhibitors
Read More
New Merck compounds selectively antagonize alpha1A-adrenoceptors
Read More
SC-744 and its active enantiomer SC-795, two new CETP inhibitors
Read More
Advantage-S study fails to demonstrate effectiveness as HIV prophylactic
Read More
Aventis receives E.U. approval for Lantus
Read More
Nutropin Depot now available
Read More
Elan receives FDA approvable letter for ziconotide
Read More